Astellas develops gene therapy based on oncolytic virus

The technology is based on a vaccinia virus which carries immunostimulatory genes. The technology has been developed by Takashi NAKAMURA at Tottori University, and Astellas has taken a worldwide exclusive license agrement. Astellas owns already ASP 8374/PTZ-201, immunity checkpoint inhibitor which introduced from Potenza Therapeutics, Inc.. ASP 8374/PTZ-201 is an antagonist against T-cell immunoreceptors with Ig and ITIM domains (TIGIT) expressed in T cells and natural killer cells.

Source: Astellas news release, March 6, 2018

Request a quote for deeper information from
contact@asia-tech.eu

© 2018 Window to Japan - Bio 4 Business - Imprint